The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The sequencing of CD19-targeting CAR-Ts and CD20-targeting bispecifics in DLBCL
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, provides a comprehensive overview of the CD19-targeting CAR-T products and CD20-targeting bispecific T-cell engagers that are currently FDA-approved for the treatment of diffuse large B-cell lymphoma (DLBCL) and considers optimal sequencing of these immunotherapies. She mentions pivotal trials that have led to the approval of CAR-T products in this patient population (ZUMA-1; NCT02348216, TRANSCEND-NHL-001; NCT02631044, JULIET; NCT03960840), as well as the bispecifics glofitamab and epcoritamab. Emphasizing the efficacy of both bispecifics and CAR-Ts in the third-line setting, Dr Kamdar suggests a preference for CAR-Ts due to their greater curative potential. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, AstraZeneca, Celgene/ Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics, Beigene, Genentech, syncopation, caribou biosciences
DMC: Genentech, Celgene
Research Funding: Novartis
Speakers Bureau: SeaGen
